Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.81 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.81 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581172 | 1.00 | ADORA3 (0.81) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL30581178 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL30579776 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL3072713 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL3072711 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5396253 | 0.89 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4136507 | 0.89 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL7080746 | 0.89 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL7080749 | 0.89 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL30581189 | 0.89 | ADORA3 (0.80) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| EP-4273153-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273153-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143740-A1 | ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江春禾医药科技有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885ADORA1 4/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.